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Abstract
Background: Metabolic syndrome is a cluster of three out of five conditions that are due to hyperinsulinemia: abdominal 
obesity, atherogenic dyslipidemia (high triglycerides and/or low HDL), elevated blood pressure, and elevated plasma glucose. 
The syndrome is highly prevalent in patients with type-2 diabetes mellitus and often precedes the onset of hyperglycemia. It 
has been shown that metabolic syndrome is an independent clinical indicator of macro- and microvascular complications in 
diabetics. Aim and objectives: the aim of this pilot study was to estimate the frequency and characteristics of metabolic 
syndrome among type-2 diabetic patients in Benghazi. Patients and methods: This cross-sectional study involved 99 randomly 
selected adult patients with type-2 diabetes mellitus. The patients were interviewed and examined, and their lipid profiles 
were checked 9-12 hours after overnight fasting. Metabolic syndrome was defined according to the criteria of the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and of the International Diabetes Federation (IDF). 
Results: About 92% of the patients had the metabolic syndrome according to ATP III criteria and 80.8% according to IDF 
criteria. Females were more affected, males with metabolic syndrome were significantly older, and females were significantly 
more obese. No significant difference was observed between males and females regarding waist circumference, HDL level and 
triglyceride level. The commonest and most important component of metabolic syndrome in the study group was low HDL. 
Conclusion: Metabolic syndrome is common among Libyans with type-2 diabetes mellitus, and it is significantly more 
common in females than males. The most significant predictor of metabolic syndrome in type-2 diabetic patients in Benghazi 
is low HDL. 
Key words: Metabolic, diabetes, hypertension, dyslipidemia, obesity, Benghazi, Libya. 
 
Introduction
Metabolic syndrome (MS) is a cluster of multiple 
cardiovascular risk factors. It is defined as the presence of 
two out of four conditions that result from insulin 
resistance: abdominal obesity, atherogenic dyslipidemia, 
elevated blood pressure, and elevated plasma glucose. In 
2001, the National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III (ATP III) proposed a set of 
easily applicable criteria to diagnose metabolic syndrome 
[1]. The criteria were modified in 2005 by the American 
Heart Association (AHA) and the National Heart, Lung and 
Blood Institute (NHBI) [2]. Other similar criteria were 
proposed in 2005 by the International Diabetes Federation 
(IDF) [3]. Compared to ATPIII, IDF criteria seem to 
overestimate the prevalence of MS without improving 
prognostic value [4,5,6]. Patients with type-2 diabetes 
mellitus (DM) already fulfill one of the NCEP-ATP III or 
IDF diagnostic criteria, and two more are required for an 
MS diagnosis. From an epidemiological point of view, the 
syndrome is highly prevalent in patients with type-2 DM, 
and it often precedes the onset of hyperglycemia [7,8,9]. 
However, much controversy surrounds the importance of 
MS in diabetics as a separate biological entity over each of 
its components as a cardiovascular risk factor [10,11,12]. 
On the other hand, many studies have shown that MS, 
irrespective of its definition, is an independent clinical 
indicator of macrovascular and microvascular 
complications in diabetics [10,11]. The objectives of this 
pilot study were as follows: 
- estimate the frequency and characteristics of MS 
among male and female type- 2 diabetic patients in 
Benghazi 
- compare the two commonly used sets of criteria, 
ATPIII and IDF. 
 
Patients and method 
This cross-sectional study involved 99 randomly selected 
adult patients with type-2 DM attending Benghazi Diabetes 
Center during 2007. Each day, nine patients were 
indiscriminately selected (unsystematic randomization). 
The patients were interviewed and examined by the 
authors, and their lipid profiles were checked 9-12 hours 
after overnight fasting. Obesity was defined according to 
WHO criteria as body mass index (BMI)   30 kg/m2. 
Hyper- tension was defined as blood pressure   140/80 
mmHg. MS was diagnosed, according to the AHA/NHLBI 
modified ATP III criteria [2], as the presence of two of the 
following four criteria:  
-waist circumference (WC)   102 cm in males or   88 
cm in females;  
- blood pressure(BP)   130/85 mmHg or on treatment,  
- triglycerides(TG)   150 mg/dl or on treatment;  
- high density lipoproteins (HDL) < 40 mg/dl in males or 
< 50 mg/dl or on treatment in females.  
Metabolic syndrome was also diagnosed according to 
IDF criteria [3] when waist circumference was   94 cm in 
males and   80 cm in females and at least one of the 
following three criteria was present: blood pressure   
130/85 mmHg, triglycerides   150 mg/dl, and high density 
lipoproteins < 40 mg/dl in males and < 50 mg/dl in 
females. Values above the cut-off points for each 
parameter were regarded as abnormal. The results were 
expressed as mean ± standard deviation (SD). Statistical 
analyses were performed using the Statistical Package for 
the Social Sciences (Windows version 11.0; SPSS Inc, 
Chicago, IL, USA). 
Differences between groups were tested statistically 
using the Chi Square test or the independent-sample t-
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test, as indicated. Data were considered statistically 
significant when the P-value was < 0.05.  
 
Results
Out of 99 patients, 61 were females and 38 were males. 
The mean age of all patients was 56 years (SD 9.5 years), 
males were slightly older, and had slightly longer duration 
of diabetes. Of all patients, 74.4% were obese, and 
obesity was significantly more frequent among females (P 
<0.001). Mean BMI was 33.6 kg/m2 (SD 5.6 kg/m2). 
There was no significant difference between males and 
females regarding WC, HDL and TG, but systolic and 
diastolic BP were slightly higher in males. The prevalence 
of hypertension (HTN) among the study group was 64% 
(Table 1). The frequency of MS was 92% according to 
ATPIII criteria and 80.8% according to IDF criteria, and 
females were significantly more affected in both cases 
(Fig. 1). Low HDL was the most significantly frequent 
abnormality according to ATPIII criteria (83.5%) while 
both low HDL and high TG were the most significantly 
frequent abnormalities according to IDF criteria (86.3% 
and 55% respectively) (Table 2). According to ATPIII, the 
mean HDL was significantly lower in both males (36 
mg/dl) and females (37.1mg/dl) with MS than those 
without MS (54.1 mg/dl and 59 mg/dl respectively, P < 
0.05) but according to IDF criteria it was significantly 
lower only in females. TG level was significantly higher in 
MS patients according to IDF criteria (191.8 vs. 115.7 
mg/dl, P=0.007) (Table 3). According to ATPIII criteria, 
males with MS were significantly older and had a higher 
mean systolic and diastolic BP than females (136.1 vs. 
126.7mmHg, P=0.05) while females were significantly 
more obese with higher mean BMI than males (35.8 vs. 
30.4 kg/m2, P=0.000) (Table 4). 
 
 
Discussion
We show that MS is quite prevalent among Libyan type-
2 diabetic patients. In fact, this prevalence is among the 
highest in the world [5,9,13,14] (Table 5). In view of the 
small sample size, larger studies would be needed to 
confirm this finding. This high frequency could be due to 
both genetic predisposition and environmental factors, 
such as high caloric diet and lack of exercise. Roaied and 
Kablan reported that only 20% of males and 58% of 
females with diabetes in Benghazi practice regular 
exercise [15]. Females were significantly more affected by 
MS than males, probably because of the higher frequency 
of obesity among females. The high rate of general and 
central obesity in our patients, particularly in females, 
endorses the importance of exercise for diabetic patients. 
There was no significant difference between males and 
females in mean waist circumference and mean HDL, 
neither in the MS patients nor in the non- MS patients. 
This raises the following question: do we need different 
cut off values for males and females for abnormal WC and 
HDL? This question requires serious investigation. 
Atherogenic dyslipidemia (high TG and/or low HDL) 
appears to be the most frequent and the most significant 
component of MS in Libyan diabetic patients, as has been 
reported in other parts of the world [16]. Thus, TG and 
HDL require particular attention in the diagnosis of MS in 
diabetic patients, unlike WC, which showed no significant 
difference between MS and non- MS Libyan diabetic 
patients, as has been reported elsewhere. For example, 
one Japanese study concluded that neither the presence 
of MS, as defined by the IDF guideline, nor the WC was 
associated with the presence of either microvascular nor 
macrovascular complications in Japanese type 2 diabetic 
patients [4]. 
Table 1 Characteristics of the entire study group (Biochemical parameters are given in mg/dl. DM= diabetes mellitus, BMI=body mass index, 
HDL= high density lipoproteins, WC= waist circumference, TG=triglyceride, SBP= systolic blood pressure, DBP= diastolic blood pressure, 
BP=Blood pressure, HTN= hypertension, MS= metabolic syndrome, ATPII=adult treatment panel III, IDF= international diabetes federation. 
P-values refer to differences between males and females) 
Males  Females  P-value  All  patients
Number   38  61   99
Age: mean±SD 
(range)
58.2±11.5
(37-76)
54.6±7.8
(39-75) 0.073  56±9.5
DM duration: mean±SD 10.7±9.6  8.7±6.5  0.22  9.4±7.8
Obesity 47.3%  91.8%  <0.001  74.4%
BMI:mean±SD
(range)
30±5.3
(16-42)
35.9±4.5
(16-42) <0.001  33.6±5.6
WC: mean±SD
(range)
102.9±11.6
(67-125)
104.2±10.5
(52-121) 0.57  103.6±10.9
Abnormal WC 55.2%  78.6%  0.014  69.6%
HDL: mean±SD 
(range)
37±14.9
(11-81)
37.8±9.9
(16-65) 0.72  38.2±13.3
Abnormal HDL 65.7%  88.5%  0.006  79.7%
TG: mean±SD 
(range)
178.2±111
(57-486)
176.6±113
(34-675) 0.94  177.2±112
Abnormal TG 47.3%  47.5%  0.98  47.4%
SBP: mean±SD  134±17.1  126.3±18.2  0.08  129.8±18
DBP: mean±SD  83.1±8.5  79.4±8.4  0.07  81.1±8.5
Abnormal BP 78.9%  73.8%  0.55  75.8%
HTN 65.8%  63.9%  0.85  64.6%
MS (ATPIII): n/n 
(%)
32/38
(84.2%)
59/61
(96.7%) 0.026 (91.9%)
MS  (IDF): : n/ 
(%)
26/38
(68.4%)
54/61
(88.5%) 0.014  80.8%
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Figure 1 Percent frequency of MS among males and females with 
type-2 DM according to IDF and modified ATPIII criteria 
Table 2 Comparison between MS and non-MS diabetic patients 
according to IDF and modified ATPIII criteria (HDL= high density 
lipoproteins, WC= waist circumference, TG=triglyceride, 
BP=Blood pressure, HTN= hypertension, MS= metabolic 
syndrome). 
  According to ATPIII   According to IDF
 
With
MS
With-
out
MS
P
With
MS
With-
out
MS
P
Raised 
WC
71.4%  50%  0.2  
100
%  
52.6%  
0.00
1  
Raised 
BP
78%  50%  
0.07
6  
77.5
%  
68.4%  0.4  
Raised 
TG
49.4%  25%  0.18  55%  15.8%  
0.00
2  
Low
HDL
83.5%  37.5%  
0.00
8  
86.3
%  
52.6%  
0.00
1  
Obesity 76.9%  50%  0.09  
78.8
%  
57.9%  0.06  
HTN 68.1%  25%  0.01  65%  63.2%  0.8  
Table 3 Comparison between mean values of different MS components among MS and non-MS diabetics according to IDF and modified 
ATPIII criteria (M=male, F=female, WC= waist circumference, BMI=body mass index, HDL= high density lipoproteins, TG=triglyceride,  
SBP= systolic blood pressure, DBP= diastolic blood pressure, MS= metabolic syndrome 
  According to ATPIII  According to IDF 
Mean±SD  With MS  Without MS  P  With MS  Without MS  P 
WC/M 104±11.4  96.8±11.5  0.16  106±7.5 96.2±15.8  0.014 
WC/F 104±10.7 105.5±7.7  0.85  104.8±8.1 99.2±22.1 0.19 
TG 183±114  108±41  0.06  191.8±118  115.7±38  0.007 
HDL/M 36  ±16.2  54.1±18.5  0.01  37.1±19 42.5±13.6 0.3 
HDL/F 37.1±9.2 59±8.4  0.002  35.8±8.3 53.5±7.3  0.000 
BMI 33.9±5.6  30.3±5  0.08  34.2±5.1  31.3±6.9  0.027 
SBP 130.3±19  120±8.9  0.16  129.8±18.4  130±16.8  0.9 
DBP 81.3±8.47 76.6±5.1  0.18  81.2±8.8  80.7±7.5  0.8 
Study limitations 
Our study sample was large enough to fulfill our aims, but 
a larger sample would be more suitable for detecting small 
differences between means.  Unfortunately, because of 
the high prevalence of MS in the study population, the 
number of patients without MS was too few to make a 
reliable comparison between patients with and without 
MS. Moreover, we did not measure HbA1c in this study, 
and this may affect the frequency of MS as well as the 
frequency of each parameter because the degree of 
glycemic control might affect the lipid profile as well as the 
weight of the patient. Despite these limitations, this pilot 
study was able to reveal important aspects of this clinical 
syndrome among diabetic patients in Libya, perhaps most 
notable of which is its very high prevalence. 
Conclusions
Metabolic syndrome is not only highly prevalent among 
the study population; it is more prevalent than reported 
worldwide. It is more common among females than   
males. Males with MS were significantly older and had a 
higher blood pressure and females were significantly more 
obese. The most significant indicator of MS in type-2 
diabetics in Benghazi is atherogenic dyslipidemia, 
particularly low HDL, but there is no significant difference 
between MS and non MS patients regarding age, disease 
duration, blood pressure or waist circumference.  
 
Although the need to diagnose MS in diabetics is 
controversial, we believe that it is worth considering 
because diabetic patients with MS need a more aggressive 
approach in management in order to achieve glucose 
control, which necessitates the use of insulin sensitizers 
and more emphasis on exercise.  
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Table-4: Comparison between males and females with MS according to IDF and modified ATPIII criteria  (Biochemical parameters are given 
in mg/dl. Means are given ± SD. Abn.=abnormal, BMI=body mass index, HDL= high density lipoproteins, WC= waist circumference, 
TG=triglyceride, HTN=hypertension, BP=blood pressure, SBP= systolic blood pressure, DBP= diastolic blood pressure, , MS= metabolic 
syndrome). 
  ATPIII IDF 
  Males Females  P  Males Females  P 
Number 32 59    26 54  
Age 58.5±10.7 54.5±7.7 0.04 59.4±9.7  53.8±7.4  0.006 
Duration 11.5±10 8.6±6.5  0.1  12.2±10.2  8.4±6.3  0.04 
Mean WC  104±11.4 104±10.7  0.98 106±7.5  104.8±8.1  0.5 
Raised WC  55.3% 78.7%  0.06  100%  100%   
Obesity  50% 91.5%  0.000  53.8%  90.7%  0.000 
Mean BMI  30.4±5.5 35.8±4.6  0.000  31.3±4.7 35.6±4.7  0.000 
Mean TG  190±115 179±114  0.66  202.8±124  186.5±117  0.5 
Raised TG  47.4% 47.5%  0.9  57.6% 53.7%  0.7 
Mean HDL  36±16.2 37±9  0.16  37.1±19.2  35.8±8.3 0.6 
Low HDL  65.8% 88.5%  0.028  73%  92.5% 0.01 
HTN 71.9% 66.1%  0.57  58.6% 64.8%  0.9 
Raised  BP  84.4% 74.6  0.28  84.6% 74% 0.29 
Mean SBP  136.1±17.2 126.7±18.5 0.05 135.4±17.9  125.8±18  0.06 
Mean DBP  84±8.7 79.7±8.3  0.055  83.4±9 79.6±8.3  0.1 
 
 
Table 5 Prevalence of metabolic syndrome among type-2 
diabetics in different countries 
Country ATPIII  IDF 
Libya 92% 80.8% 
USA[9] 70% / 
Italy[5]  68.4% 73.7% 
UK[13]  61% 54% 
China[14]  55.7% 50% 
Recommendations
- Physicians treating type-2 diabetics should place 
greater emphasis on weight reduction and exercise, which 
together should have a positive impact on patients’ 
weight, HDL and TG levels as well as on BP and glycemic 
control. 
- Metformin should be prescribed to most type-2 
diabetic patients, particularly those with MS, unless there 
is a specific contraindication. Metformin targets insulin 
resistance and thus it has positive effects on patients’ 
weight, lipid profile and glycemic control. 
- Studies of larger samples should be conducted to 
define more precisely the frequency of metabolic 
syndrome and its different components among diabetics 
and non-diabetic subjects. 
- The standard WC used in this study as defined by 
ATPIII/IDF needs to be validated for our patients, and our 
own local reference measures should be defined. 
- Prospective follow up studies are needed to identify 
the impact of MS on long-term complications of DM. 
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